News | Cardiac Imaging | March 24, 2017

Philips Showcases Data-Driven Cardiology Solutions at ACC.17

Next-generation Live 3-D TEE, highly anticipated iFR trial outcomes highlight company’s cardiovascular offerings

Philips, cardiology solutions, ACC.17, Azurion angiography system, iFR outcomes results, IntelliSpace Cardiovascular

March 24, 2017 — At the 2017 American College of Cardiology's Annual Scientific Session & Expo (ACC.17), Philips showcased a broad range of integrated, patient-centric solutions designed to address the prevention, diagnosis, minimally invasive treatment and chronic care at home of cardiac conditions.

Philips exhibited the company's advanced, connected health offerings in the cardiology space at ACC.17, including:

  • Azurion – The company’s recently launched, next-generation image-guided therapy platform allows clinicians to easily and confidently perform a wide range of routine and complex procedures, helping them to optimize interventional lab performance and provide superior care. Azurion is powered by ConnectOS, a new operating system that provides a seamless integration of real-time information from all relevant technologies in the interventional lab.
  • Evolution 3.0 – Philips introduced the X8-2t Live 3D TEE (transesophageal echo) transducer, which allows for new levels of live 3-D imaging with new 3-D TEE features, including a new acoustic design with higher frequencies and bandwidth to provide increased resolution and tissue filling. Fast, easy and confident transthoracic and transesophageal echo allows clinicians to diagnose surgical pathology in real time.
  • HeartModel AI – The company’s Anatomical Intelligence Ultrasound (AIUS) application brings advanced automated quantification, 3-D views, robust reproducibility and significant time-savings to echocardiography quantification.
  • IntelliSpace Cardiovascular – Provides access to advanced cardiovascular informatics applications, brings multimodality images and clinical tools together in a single workspace for integrated clinical decision support. It seamlessly integrates with the IntelliSpace Portal advanced visualization solution, IntelliSpace ECG (electrocardiogram) data management solution, and the Philips Xper Information Management cath lab workflow solution.
  • DreamStation BiPAP autoSV Advanced – Designed to deliver optimal ventilation with minimal intervention for patients with central sleep apnea, complex sleep apnea and periodic breathing. Philips' clinically proven algorithm provides support when needed to help reduce events and normalize ventilation, and works with the patient's breathing pattern to minimize applied pressure, pressure support and machine breaths which can help patients experience comfortable, restful sleep.

Philips also highlighted new iFR (instant wave-Free Ratio) outcome results from over 4,500 patients. The data, which represent the largest randomized coronary physiology outcome studies to date, has the potential to help shape revascularization guidelines.

Read the article “Easier to Use iFR Equal to Outcomes of FFR in Coronary Lesion Evaluation.”

In addition to presenting data around the benefits of iFR technology, Philips hosted "Cardiology Talks," a program of short talks and conversation on key findings, trends and ideas impacting the cardiology specialty today. During the 20-minute sessions, clinicians, scientists and thought leaders shared their experiences and perspectives, discussed innovations, and invited attendees to join in the conversation.

For more information: www.usa.philips.com/healthcare

Related Content

Some of the top technology news from ACC 2021. Top left, the LAAOS III trial showed benefit when surgeons seal off the LAA during other open heart procedures. Bottom left, the ReCor Paradise renal denervation system helped lower blood pressure in patients who did not respond to medication. Top right, for patients with both heart failure and AFib it makes no differences is therapy is focused on controlling the heart rhythm or heart rate. Bottom right, the FLOWER-MI trial found no benefit to FFR-guided PCI.

Some of the top technology news from ACC 2021. Top left, the LAAOS III trial showed benefit when surgeons seal off the LAA during other open heart procedures. Bottom left, the ReCor Paradise renal denervation system helped lower blood pressure in patients who did not respond to medication. Top right, for patients with both heart failure and AFib it makes no difference if therapy is focused on controlling the heart rhythm or heart rate. Bottom right, the FLOWER-MI trial found no benefit to FFR-guided PCI in STEMI with multi-vessel disease.

Feature | ACC | June 08, 2021 | By Dave Fornell, Editor
Here are the top 10 takeaways from the late-breaking studies on cardiovascular technologies presented at the 2021 ...
AMERICAN COLLEGE OF CARDIOLOGY (ACC) Late-breaking clinical trial study presentations at ACC.21. @ACC21 @ACC2021
Feature | ACC | May 18, 2021 | Dave Fornell, Editor
The latest cardiology practice-changing scientific breakthrough, late-breaking study presentations have been announce
To help monitor the health of ACC 2021 in-person attendees for signs of COVID infection, the meeting will use BioIntelliSense's wearable BioButton continuous wireless temperature and vital signs monitoring. The wearable monitor is the size of a coin and is disposable.

To help monitor the health of ACC 2021 in-person attendees for signs of COVID infection, the meeting will use BioIntelliSense's wearable BioButton continuous wireless temperature and vital signs monitoring. The wearable monitor is the size of a coin and is disposable.

News | ACC | February 09, 2021 | By Dave Fornell, Editor
UPDATE Feb 22, 2021 — ...
The American College of Cardiology (ACC) released a list of the latest practice-changing presentations at the ACC.20 annual meeting March 28-30, 2020, in Chicago. This includes five late-breaking clinical trial (LBCT) sessions and three featured clinical research sessions. There also are two LBCT deep-dive sessions where the experts will break down the hottest trials and attendees can find out what the impact might be on the practice of cardiology and patients.
Feature | ACC | April 09, 2020 | Dave Fornell, Editor
Here is the list of American College of Cardiology (ACC) practice-
ACC Cancels 2020 Conference Amid Coronavirus Concerns. #COVID19 #coronavirus #2019nCoV
Feature | ACC | March 09, 2020 | Dave Fornell, Editor
March 9, 2020 — Less than week after the American College of Cardiolog...
American College of Cardiology Names Douglas Drachman Next Annual Scientific Session Vice Chair

Image courtesy of Massachusetts General Hospital

News | ACC | October 08, 2019
Douglas Drachman, M.D., FACC, has been selected as the next vice chair of the American College of Cardiology’s (ACC)...
SyncVision iFR Co-registration from Philips Healthcare maps pressure readings onto angiogram. Results from an international study presented at ACC 2019 indicates pressure readings obtained using iFR (instantaneous wave-free ratio, also referred to as instant wave-free ratio or instant flow reserve) in coronary arteries may localize stenoses that remain after interventions. FFR in the cath lab.

SyncVision iFR Co-registration from Philips Healthcare maps pressure readings onto angiogram. Results from an international study presented at ACC 2019 indicates pressure readings obtained using iFR (instantaneous wave-free ratio, also referred to as instant wave-free ratio or instant flow reserve) in coronary arteries may localize stenoses that remain after interventions.

Feature | ACC | March 27, 2019 | Greg Freiherr, Contributing Editor
The fingerprints of value-added medicine were all over products and works-in-progress on the exhibit floor of the a

The opening late-breaking trial at ACC 2019 is the Apple Heart Study, a large-scale, app-based study to identify atrial fibrillation using a smartwatch. Earlier, smaller trials showed this approach might be used in a population health application to proactively identify AFib patients earlier.

Feature | ACC | March 19, 2019
The American College of Cardiology (ACC) released a list of the late
A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle